1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Care Facilities
DaVita Inc.

DaVita Inc.

DVA
DaVita Inc.US flagNew York Stock Exchange
195.03
USD
+7.14
- -
12.52BMarket Cap
DaVita Inc.
DVA
(New York Stock Exchange)

Recent

price

195.03

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
30.64
35.56
42.63
56.04
60.27
47.12
53.1
57.66
66.78
74.35
96.42
110.41
124.85
133.72
150.79
183.8
194.14
Revenue per Share
2
2.52
2.79
3.02
3.41
1.27
4.36
3.52
0.93
5.29
6.46
9.3
6.03
7.62
11.02
10.06
10.96
Basic EPS, GAAP
2.79
4.12
2.86
5.49
3.85
4.01
5.67
5.34
4.59
8.52
10.89
12.25
10.34
16.42
17.26
17.66
20.95
Free Cash Flow per Basic Share
0.41
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
13.39
16.88
19.43
16.02
19.25
20.56
18.4
19.27
16.06
9.35
7.12
3.37
1.88
6.59
18.06
-4.42
-2.51
Book Value per Share
-10.92
-12.47
-34.28
-28.27
-23.97
-23.76
-1.32
-4.38
-11.29
-22.35
-34.97
-46.12
-54.14
-50.36
-64.49
-89.03
-94.9
Tangible Book Value per Share
203
189
192
210
212
212
202
189
171
153
120
105
93
91
85
74
71
Basic Weighted Avg Shares
6,220
6,732
8,186
11,764
12,795
9,982
10,707
10,877
11,405
11,388
11,551
11,619
11,610
12,140
12,816
13,643
13,835
Sales/Revenue/Turnover
15.83
17.02
15.64
12.4
14
16.25
15.71
14.89
13.07
15.41
14.58
15.24
11.31
13.19
15.25
14.74
14.82
Operating Margin (%)
234
267
344
528
591
638
720
777
591
615
630
681
733
745
724
715
717
Depreciation Expense
406
478
536
633
723
270
880
664
159
811
774
978
560
692
936
747
781
Net Income, GAAP
34.92
35.49
35.94
33.87
34.08
30.14
26.6
23.14
24.65
23.39
23.81
20.2
20.5
18.7
18.27
21.76
21.77
Effective Tax Rate (%)
6.52
7.1
6.55
5.38
5.65
2.7
8.22
6.1
1.4
7.12
6.7
8.42
4.83
5.7
7.31
5.47
5.65
Profit Margin (%)
1,699
1,128
871
1,010
1,548
2,104
1,284
5,703
3,533
1,318
673
769
536
496
773
916
1,195
Working Capital
4,234
4,418
8,327
8,141
8,299
9,001
8,945
9,158
8,173
10,701
10,656
11,402
11,196
10,599
11,386
12,340
12,676
LT Debt
2,037
2,746
4,498
5,303
6,190
5,948
5,823
5,897
5,033
3,500
2,897
2,371
2,225
2,743
2,091
1,158
1,048
Total Equity
10.51
11.03
8.25
7.33
8.47
7.75
8.35
8.37
7.45
9.01
8.88
9.89
7.31
9.28
11.35
11.1
11.33
Return on Invested Capital (%)
6.8
6.99
5.77
6.18
6.52
2.83
7.22
5.88
2.49
6.68
5.7
7.07
4.54
5.57
6.95
5.8
5.86
Return on Capital (%)
16.13
16.17
15.47
17.85
19.41
6.39
21.81
18.07
5
38.85
67.73
162.12
211.87
178.93
87.79
- -
169.81
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
495
535
545
LT Borrowings
10,184
10,164
10,514
LT Finance Leases
2,100
2,176
2,162
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
71
69
66
Market Capitalization
10,264
8,437
10,953

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
4,112
4,058
4,063
Cash, Cash Equivalents & STI
736
701
667
Accounts Receivable, Net
2,333
2,415
2,459
Inventories
139
161
142
Total Current Liabilities
3,017
3,142
2,867
Payables & Accruals
736
1,171
815
ST Debt
495
535
545
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-13.26%
-13.88%
-44.61%
Free Cash Flow
8.32%
3.25%
-10.63%
Net Income, GAAP
55.21%
4.46%
-20.24%
Sales/Revenue/Turnover
3.21%
3.42%
6.46%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,071
3,187
3,264
3,295
12,816
2025
3,224
3,380
3,420
3,620
13,643
2026
3,416
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.73
2.56
2.56
3.18
11.02
2025
2.05
2.62
2.09
3.36
10.06
2026
2.93
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Nephro Care India Ltd. (NEPHROCARE-ST.NS)
Asker Healthcare Group AB (ASKER.ST)
Apollo Hospitals Enterprise Limited (APOLLOHOSP.BO)
M1 Kliniken AG (MKLNF)
Hospital Corporation of China Limited (3869.HK)
dentalcorp Holdings Ltd. (DNTL.TO)
Business
DaVita Inc. DaVita Inc. provides kidney care services, primarily dialysis treatments for patients with chronic kidney failure and end-stage kidney disease; operates approximately 2,675 outpatient dialysis centers in the United States serving more than 200,000 patients and 367 centers in 11 other countries serving around 49,400 patients; offers related laboratory services, including routine tests for dialysis patients and other physician-prescribed tests; delivers home-based hemodialysis, hospital inpatient dialysis, and acute inpatient dialysis services; provides integrated kidney care and disease management through DaVita Integrated Kidney Care for risk-based arrangements; conducts clinical research via DaVita Clinical Research since 1985 across pharmaceutical and medical device development; supports nephrologists with technology solutions through DaVita Physician Solutions; and develops innovative health care solutions for kidney disease patients through DaVita Venture Group. The company, incorporated in 1994 and formerly known as DaVita HealthCare Partners Inc. until a 2016 name change, maintains world headquarters in Denver, Colorado, and generates the majority of revenues from Medicare and government-based programs while targeting commercial payers for higher margins; it holds a 37% share of the U.S. dialysis market and operates internationally across regions including Latin America, Europe, and Asia. DaVita Inc. recently expanded internationally through 2024 acquisitions from Fresenius Medical Care for $300 million, adding over 270 clinics in Brazil, Colombia, Chile, and Ecuador to become Latin America's largest dialysis provider; entered new markets in Ecuador and Chile while deepening presence in Colombia; refinanced debt with a new $1.9 billion Term Loan B-2 and $3.5 billion credit facilities including a $2 billion Term Loan A-2 and $1.5 billion revolving facility in 2025; issued $1 billion in senior notes due 2033; and reported Q3 2025 revenues of $3.42 billion amid volume challenges from flu season, Hurricane Helene, and a cyber incident.

Company News

APIChat

  • zacks.com

    DaVita Gains 21.4% in Three Months: How Should You Play the Stock?

  • zacks.com

    Best Growth Stocks to Buy for June 2nd

  • zacks.com

    Why DaVita HealthCare (DVA) is a Top Momentum Stock for the Long-Term

  • zacks.com

    Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term

  • zacks.com

    Best Growth Stocks to Buy for May 26th

  • zacks.com

    New Strong Buy Stocks for May 26th

  • zacks.com

    Is DaVita (DVA) Stock Undervalued Right Now?

  • zacks.com

    4 High-Growth GARP Stocks With Attractive PEG Ratios for 2026

  • zacks.com

    4 Stocks Trading Near 52-Week High With Room to Rise Further

  • zacks.com

    Best Value Stocks to Buy for May 21st

  • zacks.com

    Best Growth Stocks to Buy for May 21st

  • zacks.com

    Best Value Stocks to Buy for May 19th

  • zacks.com

    Best Growth Stocks to Buy for May 19th

  • gurufocus.com

    DaVita Sets Bold 2030 Community Care Commitments After Exceeding Prior Five-Year ESG Goals

  • prnewswire.com

    DaVita Sets Bold 2030 Community Care Commitments After Exceeding Prior Five-Year ESG Goals

  • zacks.com

    4 Best Low-PEG Value Stocks to Bet On for Higher Returns

  • zacks.com

    Best Growth Stocks to Buy for May 14th

  • seekingalpha.com

    DaVita Inc. (DVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

  • zacks.com

    Here's Why DaVita HealthCare (DVA) is a Strong Momentum Stock

  • zacks.com

    Best Growth Stocks to Buy for May 12th